VERAXA Biotech and ATUM Collaborate on BiTAC-TCE Cell Line Development
VERAXA Biotech collaborates with ATUM on cell line development for BiTAC-TCE program, aiming to enhance tumor selectivity and reduce toxicity in cancer therapy.
This news matters because VERAXA's novel BiTAC-TCE platform could revolutionize cancer therapy by improving tumor selectivity and reducing toxicity, potentially leading to safer and more effective treatments for patients. The collaboration with ATUM accelerates development toward clinical trials, bringing hope for better outcomes in solid tumor cancers.